| Date Filed | Type | Description |
| 10/12/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/16/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders... |
| 06/02/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/30/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
8-K
| Termination of a Material Definitive Agreement, Other Events Interactive Data |
| 04/03/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 04/03/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/31/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/31/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/06/2023 |
8-K
| Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review  ... |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/08/2023 |
4
| Maccecchini Maria-Luisa (President and CEO) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Exercised 52,755 options to buy
@ $0.14, valued at
$7.4k
|
|
| 01/20/2023 |
4
| Maccecchini Maria-Luisa (President and CEO) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 21,312 options to buy
@ $13.17, valued at
$280.7k
|
|
| 01/20/2023 |
4
| Hagopian Henry III (CFO) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 7,672 options to buy
@ $13.17, valued at
$101k
|
|
| 01/20/2023 |
4
| White Mark K. (Director) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 5,967 options to buy
@ $13.17, valued at
$78.6k
|
|
| 01/20/2023 |
4
| McCarthy Reid (Director) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 5,967 options to buy
@ $13.17, valued at
$78.6k
|
|
| 01/20/2023 |
4
| Hoffman Michael B (10% Owner) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 6,820 options to buy
@ $13.17, valued at
$89.8k
|
|
| 01/20/2023 |
4
| Bruck Claudine (Director) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 5,967 options to buy
@ $13.17, valued at
$78.6k
|
|
| 01/06/2023 |
8-K
| Investor presentation |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/12/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/31/2022 |
4
| Hagopian Henry III (CFO) has filed a Form 4 on Annovis Bio, Inc.|
Txns:
| Granted 120,000 options to buy
@ $11.55, valued at
$1.4M
|
|
| 08/31/2022 |
3
| Hagopian Henry III (CFO) has filed a Form 3 on Annovis Bio, Inc. |
| 08/30/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
|